-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: BIOtechNOW Editor
The Fight to Combat Illegal Online Pharmacies
By Marjorie Clifton, Executive Director, Center for Safe Internet Pharmacies Over 96 percent of websites claiming to sell prescription medications are out of compliance with U.S. pharmacy laws and practice standards. The Partnership at Drugfree.org estimates that one in six Americans, approximately 36 million people have bought medication online without a valid prescription. In 2010, the U.S. market alone accounted for an estimated $75 billion in sales for counterfeit drug makers; a lucrative prospect for Read More >
Developments in the creation of a single EU Patent System stalled – Again.
By Catherine McLoughlin, specialist solicitor for Biotech and Pharmaceutical Companies, Pannone LLP After 40 years of squabbling it was hoped that the European Union was close to finally establishing a single patent system. Following a decision ending six months of stalemate from the European Council on the location of three patent courts the European Parliament has refused to put the proposal for a single European patent to a vote. This brings further delays to the Read More >
Pharmaceuticals Play a Key Role in Value-Based Care
By Dan Leonard, President, National Pharmaceutical Council Public and private sector health care stakeholders have been struggling with how best to achieve the triple aim of better care for individuals, improved health for populations, and slower cost growth. Figuring out the best health care delivery structures and approaches is a complex challenge with many variables and moving parts. That’s why there is a great deal of debate and research into what changes can support the Read More >
FDA Safety and Innovation Act: A Step Forward for Patients With Rare Diseases
By Peter L. Saltonstall, President and CEO, National Organization for Rare Disorders (NORD) The Food and Drug Administration Safety and Innovation Act (FDASIA) includes the most groundbreaking measures for rare disease patients and their families since the Orphan Drug Act of 1983. And, just as the rare disease patient community—with NORD as its unifying voice—played a major role in the Orphan Drug Act, NORD and rare disease patients have taken a leadership role in developing Read More >
The Cause Endures
By David Welch, M2 MultiMedia Communications In producing this short form mini-documentary, I learned that neither the conservatives who tried always to make Senator Ted Kennedy the poster child of all that was liberal nor the die-hard liberals who adored his every move had him quite right. This is especially true when examining his aggressive pursuit of his lifelong cause to improve the health of patients. It was a cause that propelled him into an Read More >
